Unique ID issued by UMIN | UMIN000009584 |
---|---|
Receipt number | R000011247 |
Scientific Title | Efficacy and safety of palonosetron and dexamethasone in patients who haven't responded to conventional antiemetic agents; granisetron and dexamethasone |
Date of disclosure of the study information | 2012/12/19 |
Last modified on | 2020/06/11 13:51:13 |
Efficacy and safety of palonosetron and dexamethasone in patients who haven't responded to conventional antiemetic agents; granisetron and dexamethasone
Efficacy and safety of palonosetron and dexamethasone in patients who haven't responded to conventional antiemetic agents; granisetron and dexamethasone
Efficacy and safety of palonosetron and dexamethasone in patients who haven't responded to conventional antiemetic agents; granisetron and dexamethasone
Efficacy and safety of palonosetron and dexamethasone in patients who haven't responded to conventional antiemetic agents; granisetron and dexamethasone
Japan |
Colorectal cancer
Gastrointestinal surgery |
Malignancy
NO
To evaluate the efficacy and safety of palonosetron and dexamethasone in patients who haven't responded to conventional antiemetic agents; granisetron and dexamethasone.
Safety,Efficacy
Complete Response rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Day 1
Palonosetoron 0.75mg/body and dexamethasone 12mg/body should be administered 30 minutes prior to chemotherapy
Day 2-3
Dexamethasone 4mg/body should be administered orally.
20 | years-old | <= |
Not applicable |
Male and Female
1. Pathologically colorectal cancer
2. Age; more than 20 years-old at registration
3. Performance status of 0-2
4. Patients receiving moderate emetic chemotherapy including oxaliplatin or irinotecan
5. Patients who has vomited(including dry-vomiting) or been administered additional rescue
6. Adequate organ function
7. Written informed consent
1. Severe complication(s), e.g., congestive cardiac failure, coronary failure, cardiac infarction, angina pectoris, arrhythmia, cerebrovascular accident, active gastrointestinal tract ulcer, diabetes, renal failure, hepatic failure, active hepatitis or hepatic cirrhosis.
2. Symptomatic brain metastasis
3.Epilepsy patient treated with antiepileptic agent, exclusing being stable clinically
4.Combination radiotherapy
5. History of serious drug hypersensitivity for 5-HT3RA or dexamethasone.
6. History of administration of palonosetoron
7. Pregnant, nursing mothers or man who don't agree with contraception
8.Unsuitable patients judged by investigator
30
1st name | |
Middle name | |
Last name | Kazuhiro Yoshida |
Gifu University graduate school of medicine
Department of surgical oncology
1-1 Yanagido, Gifu city
058-230-6235
kyoshida@gifu-u.ac.jp
1st name | |
Middle name | |
Last name | Takao Takahashi |
Gifu University graduate school of medicine
Department of surgical oncology
1-1 Yanagido, Gifu city
058-230-6235
takaota@gifu-u.ac.jp
Gifu University graduate school of medicine
None
Self funding
NO
2012 | Year | 12 | Month | 19 | Day |
Unpublished
Completed
2012 | Year | 07 | Month | 04 | Day |
2012 | Year | 07 | Month | 04 | Day |
2012 | Year | 07 | Month | 05 | Day |
2016 | Year | 12 | Month | 31 | Day |
2018 | Year | 03 | Month | 01 | Day |
2018 | Year | 03 | Month | 19 | Day |
2018 | Year | 11 | Month | 03 | Day |
2012 | Year | 12 | Month | 19 | Day |
2020 | Year | 06 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011247